The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...
Hosted on MSN2mon
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for reviewRegeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...
Dupixent pen and syringe are two different devices used to inject the drug. They’re prefilled with the same amount of Dupixent and share other features, but certain factors make the pen easier ...
The EMA has started a review of Leo Pharma’s interleukin-13 ... a category that is currently dominated by Sanofi and Regeneron’s Dupixent. The EU regulator is reviewing tralokinumab for ...
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...
Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback